K. Dvir, G. G. Fortuna, Nathaly Cortez, V. Guerra, M. Cusnir
{"title":"个体化医疗时代胆管癌治疗进展","authors":"K. Dvir, G. G. Fortuna, Nathaly Cortez, V. Guerra, M. Cusnir","doi":"10.17352/ojh.000004","DOIUrl":null,"url":null,"abstract":"Cholangiocarcinoma is amongst the most common primary tumors of the liver, second only to hepatocellular carcinoma, and it accounts for approximately 15% of primary hepatic malignancies [1].","PeriodicalId":288820,"journal":{"name":"Open Journal of Hepatology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Advances in Cholangiocarcinoma Treatment in the Personalized Medicine Era\",\"authors\":\"K. Dvir, G. G. Fortuna, Nathaly Cortez, V. Guerra, M. Cusnir\",\"doi\":\"10.17352/ojh.000004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cholangiocarcinoma is amongst the most common primary tumors of the liver, second only to hepatocellular carcinoma, and it accounts for approximately 15% of primary hepatic malignancies [1].\",\"PeriodicalId\":288820,\"journal\":{\"name\":\"Open Journal of Hepatology\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Journal of Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17352/ojh.000004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Journal of Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17352/ojh.000004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Advances in Cholangiocarcinoma Treatment in the Personalized Medicine Era
Cholangiocarcinoma is amongst the most common primary tumors of the liver, second only to hepatocellular carcinoma, and it accounts for approximately 15% of primary hepatic malignancies [1].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
